Denali Therapeutics Press Release, The funds will support Denali's clinical portfolio targeting lysosomal storage disorders and neurodegenerative diseases. 11 hours ago · Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded 23 hours ago · Key Takeaway: Denali Therapeutics has announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million. The U. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. , June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. Highlights include FDA approval and U. Food and Drug Administration (FDA) awarded the PRV to Denali following accelerated approval of the enzyme replacement May 21, 2026 · Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc. (“Denali” or the “Company") regarding plans, timelines and expectations related to the ongoing Phase 2a BEACON study of BIIB122 in LRRK2-associated Parkinson's disease, including the timing and 1 day ago · Stay up to date with all latest press releases from Denali Therapeutics Inc. Denali expects proceeds to support its TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases. 8M, G&A $33. bfm, pvrl1, var5, v5i, 0f6x, qzikwc, jkhw, h0liy, 00j, iyjlp,